Related Experiment Video

Updated: Dec 26, 2025

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

1.1K

Galectin-3 Is a Potential Mediator for Atherosclerosis

Ziyu Gao1,2, Zhongni Liu2, Rui Wang3

  • 1State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing 100037, China.

Journal of Immunology Research
|March 10, 2020
PubMed

Insights

Galectin-3 (Gal-3) is an inflammatory factor involved in atherosclerosis, a key cause of cardiovascular diseases. This review explores Gal-3

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Molecular Medicine

Background:

  • Atherosclerosis is a chronic inflammatory arterial disease underlying major cardiovascular diseases like heart attack and stroke.
  • Inflammation is recognized as a critical factor in atherosclerosis development and progression.

Purpose of the Study:

  • To review the role of Galectin-3 (Gal-3) in atherosclerosis.
  • To elucidate the mechanisms by which Gal-3 influences atherosclerotic processes.
  • To summarize current Gal-3 agonists and antagonists in atherosclerosis research.

Main Methods:

  • Literature review of studies on Galectin-3 and atherosclerosis.
  • Analysis of Gal-3's involvement in inflammatory pathways.
  • Examination of Gal-3's role in lipid metabolism and cellular processes within arteries.

Main Results:

  • Galectin-3 (Gal-3) acts as a novel inflammatory factor in atherosclerosis.
  • Gal-3 participates in key processes including intravascular inflammation, lipid uptake, macrophage activation, cell proliferation, and adhesion.
  • Various Gal-3 modulators have been investigated in preclinical studies.

Conclusions:

  • Galectin-3 is a significant mediator in the pathogenesis of atherosclerosis.
  • Targeting Gal-3 presents a potential therapeutic strategy for cardiovascular diseases.
  • Further research into Gal-3's mechanisms and modulators is warranted.

More Related Videos

Flow Cytometry Analysis of Immune Cells Within Murine Aortas15:15

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Published on: July 1, 2011

35.2K
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.7K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
272
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
684
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
386
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
290
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
248
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
300